Literature DB >> 3813090

Hyperkalemia, verapamil, and dantrolene.

A S Rubin, A D Zablocki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3813090     DOI： 10.1097/00000542-198702000-00028

Source DB:  PubMed          Journal:  Anesthesiology        ISSN： 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  8 in total

Review 1.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 2.  Calcium-channel blockers and anaesthesia.

Authors:  P G Durand; J J Lehot; P Foëx
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

Review 3.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 4.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

5.  Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States.

Authors:  Barbara W Brandom; Marilyn Green Larach; Min-Shue Alvin Chen; Michael C Young
Journal:  Anesth Analg       Date:  2011-03-03       Impact factor: 5.108

Review 6.  Malignant hyperthermia.

Authors:  R Ben Abraham; P Adnet; V Glauber; A Perel
Journal:  Postgrad Med J       Date:  1998-01       Impact factor: 2.401

7.  Cardiac implications of amlodipine-dantrolene combinations.

Authors:  M Freysz; Q Timour; C Bernaud; L Bertrix; G Faucon
Journal:  Can J Anaesth       Date:  1996-01       Impact factor: 5.063

Review 8.  Malignant hyperthermia: a review.

Authors:  Henry Rosenberg; Neil Pollock; Anja Schiemann; Terasa Bulger; Kathryn Stowell
Journal:  Orphanet J Rare Dis       Date:  2015-08-04       Impact factor: 4.123
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.